TechCrunch LA

MAY 25, 2019

For one, because millennials, according to various studies, are consuming less alcohol than previous generations and are therefore seeking non-alcoholic beverage alternatives. From wellness chat and journaling apps to therapy substitutes to fitness companies, stick wellness in a pitch and investors will take a second look. Fundraising.

Startup 223

Startup Venture Capital Newsletter Tips 223

Xconomy

OCTOBER 7, 2016

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. PRICE FIGHTS. With some caveats, ICER recommended lower prices. She refused to discuss Edison at the time. —The U.S.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. The company plans to present detailed results at an upcoming medical meeting or in a peer-reviewed journal, it said in a statement.

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

APRIL 20, 2018

The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options?

Pricing 52

Pricing News Report Develop 52

Xconomy

AUGUST 12, 2016

Celgene paid Acetylon $100 million in 2013 for an option to buy the company outright, but the deal recently expired without an acquisition, leaving Acetylon to chart a new course. . —Option-to-buy deals are by definition no guarantee, and an agreement between Boston-based Acetylon Pharmaceuticals and Celgene is the latest example.

Google 40

Google Technical Review News Research 40

Tech Zulu Event

APRIL 10, 2012

Things you don’t read about in the Wall St Journal. The craziest part is that studies have started to show that users who download an app for free are likely to spend more than $0.99 App prices change all of the time. Doesn’t it seem like its every person you see has an iPhone? Why not right? Distribution is everything.

Mobile 82

Mobile Search Engine Optimization SEO Startup 82